Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy IGM Biosciences stock | 54

Own IGM Biosciences stock in just a few minutes.

Posted

Fact checked

IGM Biosciences, Inc is a biotechnology business based in the US. IGM Biosciences shares (IGMS) are listed on the NASDAQ and all prices are listed in US Dollars. IGM Biosciences employs 91 staff and has a market cap (total outstanding shares value) of USD$2.3 billion.

How to buy shares in IGM Biosciences

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for IGM Biosciences. Find the stock by name or ticker symbol: IGMS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until IGM Biosciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$54, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of IGM Biosciences, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of IGM Biosciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted IGM Biosciences's share price?

Since the stock market crash in March caused by coronavirus, IGM Biosciences's share price has had significant negative movement.

Its last market close was USD$54, which is 11.02% down on its pre-crash value of USD$60.69 and 96.01% up on the lowest point reached during the March crash when the shares fell as low as USD$27.55.

If you had bought USD$1,000 worth of IGM Biosciences shares at the start of February 2020, those shares would have been worth USD$1,327.66 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,388.34.

IGM Biosciences share price

Use our graph to track the performance of IGMS stocks over time.

IGM Biosciences shares at a glance

Information last updated 2020-10-19.
Latest market close USD$54
52-week range USD$18.89 - USD$89.81
50-day moving average USD$68.3203
200-day moving average USD$61.3064
Wall St. target price USD$82.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-71.751

Buy IGM Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy IGM Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

IGM Biosciences price performance over time

Historical closes compared with the close of $54 from 2020-11-16

1 week (2020-11-17) 0.43%
1 month (2020-10-27) -10.55%
3 months (2020-08-25) 18.76%
6 months (2020-05-23) N/A
1 year (2019-11-25) 139.79%
2 years (2018-11-23) N/A
3 years (2017-11-23) N/A
5 years (2015-11-23) N/A

IGM Biosciences financials

Gross profit TTM USD$-22,649,000
Return on assets TTM -29.09%
Return on equity TTM -49.4%
Profit margin 0%
Book value $8.354
Market capitalisation USD$2.3 billion

TTM: trailing 12 months

Shorting IGM Biosciences shares

There are currently 1.6 million IGM Biosciences shares held short by investors – that's known as IGM Biosciences's "short interest". This figure is 0.8% up from 1.6 million last month.

There are a few different ways that this level of interest in shorting IGM Biosciences shares can be evaluated.

IGM Biosciences's "short interest ratio" (SIR)

IGM Biosciences's "short interest ratio" (SIR) is the quantity of IGM Biosciences shares currently shorted divided by the average quantity of IGM Biosciences shares traded daily (recently around 224939.16786227). IGM Biosciences's SIR currently stands at 6.97. In other words for every 100,000 IGM Biosciences shares traded daily on the market, roughly 6970 shares are currently held short.

However IGM Biosciences's short interest can also be evaluated against the total number of IGM Biosciences shares, or, against the total number of tradable IGM Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case IGM Biosciences's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 IGM Biosciences shares in existence, roughly 50 shares are currently held short) or 0.2205% of the tradable shares (for every 100,000 tradable IGM Biosciences shares, roughly 221 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against IGM Biosciences.

Find out more about how you can short IGM Biosciences stock.

IGM Biosciences share dividends

We're not expecting IGM Biosciences to pay a dividend over the next 12 months.

IGM Biosciences overview

IGM Biosciences, Inc., a biotechnology company, engages in the research and development of Immunoglobulin M (IgM) antibodies for the treatment of cancer. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with B cell NHL and other B cell malignancies. It is also developing IGM-8444, an IgM antibody targeting Death Receptor 5 proteins; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. IGM Biosciences, Inc. has a collaboration with Atreca Inc. and BeiGene Ltd. to discover, develop, and manufacture novel IgM and IgA antibodies targeting SARS-CoV-2 for the potential treatment of COVID-19; and strategic research collaboration and license agreement with AbCellera to discover and develop IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site